On Thursday, biotech stocks and research shares experienced different trajectories following reports indicating the FDA's imminent mandate of a single pivotal study. This development caused concerns for Medpace and Iqvia but resulted in gains for Viking Therapeutics. The potential policy change reflects a shift in regulatory requirements and could significantly impact the industry.